ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,623.29
0.61%
Dow Jones
44,881.84
0.73%
Gold vs US Dollar
2,863.34
0.75%
Brent Oil
74.645
-1.71%
Bitcoin
97,734.03
-0.13%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Johnson & Johnson (0R34)

  7. Johnson & Johnson (0R34) News

Johnson & Johnson (0R34)

Johnson & Johnson
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0R34
DateTimeSourceHeadlineSymbolCompany
03/02/202510:44Alliance NewsAlliance NewsJ&J secures CHMP backing for subcutaneous Rybrevant in lung cancerLSE:0R34Johnson & Johnson
22/01/202512:03Alliance NewsAlliance NewsJohnson & Johnson reports sales growth following "transformative year"LSE:0R34Johnson & Johnson
13/01/202512:36Alliance NewsAlliance NewsJ&J acquires schizophrenia drug in USD14.6 billion Intra-Cellular dealLSE:0R34Johnson & Johnson
20/11/202414:13Alliance NewsAlliance NewsJohnson & Johnson risks UK lawsuit over talc cancer claimLSE:0R34Johnson & Johnson
15/10/202411:36Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson ups sales outlook but cuts profit guideLSE:0R34Johnson & Johnson
09/10/202418:36Alliance NewsAlliance NewsTOP NEWS: J&J USD600 million V-Wave purchase to cut earnings per shareLSE:0R34Johnson & Johnson
20/08/202412:12Alliance NewsAlliance NewsJ&J to pay up to USD1.7 billion for heart failure device firm V-WaveLSE:0R34Johnson & Johnson
17/07/202411:25Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson touts "robust pipeline" as sales riseLSE:0R34Johnson & Johnson
31/05/202413:30Alliance NewsAlliance NewsJohnson & Johnson ties up acquisition of Shockwave MedicalLSE:0R34Johnson & Johnson
01/05/202413:17Alliance NewsAlliance NewsTOP NEWS: J&J proposes USD6.48 billion settlement of cancer lawsuitsLSE:0R34Johnson & Johnson
16/04/202410:54Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson upgrades guidance on swing to earningsLSE:0R34Johnson & Johnson
05/04/202411:02Alliance NewsAlliance NewsTOP NEWS: J&J swoops for Shockwave Medical in USD13.1 billion dealLSE:0R34Johnson & Johnson
25/03/202418:28Alliance NewsAlliance NewsIN BRIEF: J&J submits US premarket approval application for VaripulseLSE:0R34Johnson & Johnson
18/03/202411:10Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson receives FDA recommendation for CarvyktiLSE:0R34Johnson & Johnson
23/02/202418:32Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson gets EMA nod for Carvykti in myelomaLSE:0R34Johnson & Johnson
02/02/202406:22Alliance NewsAlliance NewsTOP NEWS: US sends drugmakers initial offers in Medicare price talksLSE:0R34Johnson & Johnson
23/01/202411:41Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson eyes future growth; 2023 sales riseLSE:0R34Johnson & Johnson
19/01/202421:34Alliance NewsAlliance NewsIN BRIEF: J&J gets US FDA approval for cancer treatment BalversaLSE:0R34Johnson & Johnson
05/12/202313:24Alliance NewsAlliance NewsTOP NEWS: J&J expects strong long-term growth in three key driversLSE:0R34Johnson & Johnson
23/10/202311:03Alliance NewsAlliance NewsJ&J report slew of positive trial results focused on various cancersLSE:0R34Johnson & Johnson
17/10/202310:46Alliance NewsAlliance NewsTOP NEWS: J&J raises full-year sales outlook after "solid" quarterLSE:0R34Johnson & Johnson
06/10/202315:52Alliance NewsAlliance NewsIN BRIEF: J&J applies for indication extension to EMA for RybrevantLSE:0R34Johnson & Johnson
03/10/202316:00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0R34Johnson & Johnson
07/09/202305:50Alliance NewsAlliance NewsJ&J's Janssen ends Phase 3 MACiTEPH study evaluating macitentanLSE:0R34Johnson & Johnson
30/08/202316:07Alliance NewsAlliance NewsTOP NEWS: J&J forecasts strong growth in earnings after Kenvue splitLSE:0R34Johnson & Johnson
10/08/202320:34Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson's blood cancer therapy approved by FDALSE:0R34Johnson & Johnson
20/07/202311:30Alliance NewsAlliance NewsTOP NEWS: J&J ups full-year guidance after "robust" second quarterLSE:0R34Johnson & Johnson
30/05/202315:48Alliance NewsAlliance NewsJ&J seeks FDA approval for pulmonary arterial hypertension treatmentLSE:0R34Johnson & Johnson
09/05/202319:23Alliance NewsAlliance NewsJ&J says Tremfya data shows positive results for ulcerative colitisLSE:0R34Johnson & Johnson
04/05/202311:41Alliance NewsAlliance NewsIN BRIEF: J&J prices subsidiary Kenvue's NYSE initial public offeringLSE:0R34Johnson & Johnson
 Showing the most relevant articles for your search:LSE:0R34

Your Recent History

BIT
UC4SSX
Unicredit Bank
NASDAQ
FCLNX
Beutel Goodman Total Wor...
BIT
F36217
Vontobel Financial Produ...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads